Insulin Makers Can't Nix 340B Antitrust Claims On Remand
By Gianna Ferrarin · June 29, 2026, 6:21 PM EDT
A New York federal judge trimmed proposed class action claims by providers alleging Sanofi-Aventis and other drugmakers colluded to deny them discounts on insulin products under the 340B program, allowing most...
To view the full article, register now.